Concealed urogenital schistosomiasis causing chronic pelvic pain: A case report

Karaga, Rumbidzai Majangara

doi:10.1002/ccr3.3654

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In sub-Saharan Africa where UGS is endemic and can be highly prevalent (>50%),14 15 insufficient or infrequent efforts have been undertaken to document FGS specifically,11 16–18 partly as the clinical skills to do so are lacking and uninformed within primary care 10. While active UGS does not readily predict FGS,6 since FGS can occur without the direct presence of schistosome eggs in urine (a cardinal diagnostic for UGS),18 19 rather FGS often presents with a more chronic time frame where schistosome eggs are trapped within the cervicovaginal surfaces 6 20 21. For some, these trapped eggs can accumulate from very early on in life,1 with enduring and typically hidden sequelae 20 22.…”

Section: Introductionmentioning

confidence: 99%

Urogenital schistosomiasis (UGS) and female genital schistosomiasis (FGS) in Cameroon: an observational assessment of key reproductive health determinants of girls and women in the Matta Health Area

Masong

Fesuh

Amabo³

et al. 2023

BMJ Open

View full text Add to dashboard Cite

Objectives and settingAcross sub-Saharan Africa, urogenital schistosomiasis (UGS), in particular female genital schistosomiasis (FGS), is a significant waterborne parasitic disease, with its direct burden on the sexual and reproductive health (SRH) of sufferers infrequently measured. UGS has an established control plan, which in most endemic regions as in Cameroon, still excludes FGS considerations. Highlighting existent associations between UGS and FGS could increase the management of FGS within UGS interventions. This study seeks to identify current associations among FGS and UGS with some reproductive health indicators, to provide formative information for better integrated control.Participants304 females aged 5–69 years were all examined for UGS by urine filtration and microscopy. Among these, 193 women and girls were eligible for clinical FGS assessment based on age (>13). After selective questioning for FGS symptoms, a subgroup of 67 women and girls consented for clinical examination for FGS using portable colposcopy, with observed sequelae classified according to the WHO FGS pocket atlas.OutcomeOverall UGS and FGS prevalence was measured, with FGS-related/UGS-related reproductive health symptoms recorded. Associations between FGS and UGS were investigated by univariate and multivariate logistic regression analyses.ResultsOverall UGS prevalence was 63.8% (194/304), where FGS prevalence (subgroup) was 50.7% (34/67). FGS manifestation increased significantly with increasing age, while a significant decrease with ascending age was observed for UGS. Lower abdominal pain (LAP) vaginal itches (VI) and coital pain (CP) were identified as the main significant shared symptoms of both FGS and UGS, while LAP with menstrual irregularity (MI) appeared a strong symptomatic indicator for FGS.ConclusionLAP, MI, CP and VI are the potential SRH indicators that could be exploited in future for targeting of praziquantel provision to FGS sufferers within primary care, complementary with existing praziquantel distribution for UGS sufferers inSchistosoma haematobiumendemic areas.

show abstract